The present invention pertains to the field of apparatus for treatment of a failing heart. In particular, the apparatus of the present invention is directed toward reducing the wall stress in the failing heart.
The syndrome of heart failure is a common course for the progression of many forms of heart disease. Heart failure may be considered to be the condition in which an abnormality of cardiac function is responsible for the inability of the heart to pump blood at a rate commensurate with the requirements of the metabolizing tissues, or can do so only at an abnormally elevated filling pressure. There are many specific disease processes that can lead to heart failure with a resulting difference in pathophysiology of the failing heart, such as the dilatation of the left ventricular chamber. Etiologies that can lead to this form of failure include idiopathic cardiomyopathy, viral cardiomyopathy, and ischemic cardiomyopathy.
The process of ventricular dilatation is generally the result of chronic volume overload or specific damage to the myocardium. In a normal heart that is exposed to long term increased cardiac output requirements, for example, that of an athlete, there is an adaptive process of slight ventricular dilation and muscle myocyte hypertrophy. In this way, the heart fully compensates for the increased cardiac output requirements. With damage to the myocardium or chronic volume overload, however, there are increased requirements put on the contracting myocardium to such a level that this compensated state is never achieved and the heart continues to dilate.
The basic problem with a large dilated left ventricle is that there is a significant increase in wall tension and/or stress both during diastolic filling and during systolic contraction. In a normal heart, the adaptation of muscle hypertrophy (thickening) and ventricular dilatation maintain a fairly constant wall tension for systolic contraction. However, in a failing heart, the ongoing dilatation is greater than the hypertrophy and the result is a rising wall tension requirement for systolic contraction. This is felt to be an ongoing insult to the muscle myocyte resulting in further muscle damage. The increase in wall stress is also true for diastolic filling. Additionally, because of the lack of cardiac output, there is generally a rise in ventricular filling pressure from several physiologic mechanisms. Moreover, in diastole there is both a diameter increase and a pressure increase over normal, both contributing to higher wall stress levels. The increase in diastolic wall stress is felt to be the primary contributor to ongoing dilatation of the chamber.
Prior art treatments for heart failure fall into three generally categories. The first being pharmacological, for example, diuretics. The second being assist systems, for example, pumps. Finally, surgical treatments have been experimented with, which are described in more detail below.
With respect to pharmacological treatments, diuretics have been used to reduce the workload of the heart by reducing blood volume and preload. Clinically, preload is defined in several ways including left ventricular end diastolic pressure (LVEDP), or left ventricular end diastolic volume (LVEDV). Physiologically, the preferred definition is the length of stretch of the sarcomere at end diastole. Diuretics reduce extra cellular fluid which builds in congestive heart failure patients increasing preload conditions. Nitrates, arteriolar vasodilators, angiotensin converting enzyme inhibitors have been used to treat heart failure through the reduction of cardiac workload through the reduction of afterload. Afterload may be defined as the tension or stress required in the wall of the ventricle during ejection. Inotropes like digoxin are cardiac glycosides and function to increase cardiac output by increasing the force and speed of cardiac muscle contraction. These drug therapies offer some beneficial effects but do not stop the progression of the disease.
Assist devices include mechanical pumps and electrical stimulators. Mechanical pumps reduce the load on the heart by performing all or part of the pumping function normally done by the heart. Currently, mechanical pumps are used to sustain the patient while a donor heart for transplantation becomes available for the patient. Electrical stimulation such as bi-ventricular pacing have been investigated for the treatment of patients with dilated cardiomyopathy.
There are at least three surgical procedures for treatment of heart failure: 1) heart transplant; 2) dynamic cardiomyoplasty; and 3) the Batista partial left ventriculectomy. Heart transplantation has serious limitations including restricted availability of organs and adverse effects of immunosuppressive therapies required following heart transplantation. Cardiomyoplasty includes wrapping the heart with skeletal muscle and electrically stimulating the muscle to contract synchronously with the heart in order to help the pumping function of the heart. The Batista partial left ventriculectomy includes surgically remodeling the left ventricle by removing a segment of the muscular wall. This procedure reduces the diameter of the dilated heart, which in turn reduces the loading of the heart. However, this extremely invasive procedure reduces muscle mass of the heart.
The present invention pertains to a non-pharmacological, passive apparatus for the treatment of a failing heart. The device is configured to reduce the tension in the heart wall. It is believed to reverse, stop or slow the disease process of a failing heart as it reduces the energy consumption of the failing heart, decrease in isovolumetric contraction, increases sarcomere shortening during contraction and an increase in isotonic shortening in turn increases stroke volume. In embodiments, the device reduces wall tension during diastole (preload) and systole.
In an embodiment, the apparatus includes a compression member for drawing at least two walls of a heart chamber toward each other to reduce the radius or area of the heart chamber in at least one cross sectional plane. In one embodiment of the apparatus, a frame is provided for supporting the compression member.
Yet another embodiment of the invention includes a damp having two ends biased toward one another for drawing at least two walls of a heart chamber toward each other. The damp includes at least two ends having atraumatic anchoring member disposed thereon for engagement with the heart or chamber wall.
The present invention also pertains to a device and method for reducing mechanical heart wall muscle stress. Heart muscle stress is a stimulus for the initiation and progressive enlargement of the left ventricle in heart failure. Reduction of heart wall stress with the devices and methods disclosed herein is anticipated to substantially slow, stop or reverse the heart failure disease process. Although the primary focus of the discussion of the devices and methods of the present invention herein relates to heart failure and the left ventricle, these devices and method could be used to reduce stress in the hearts other chambers.
The devices and methods of the present invention can reduce heart wall stress throughout the cardiac cycle including end diastole and end systole. Alternatively, they can be used to reduce wall stress during the portions of the cardiac cycle not including end systole. Those devices which operate throughout the cardiac cycle are referred to herein as “full cycle splints”. Those devices which do not operate to reduce wall stress during end stage systole are referred to as “restrictive devices”. Restrictive devices include both “restrictive splints” which alter the geometric shape of the left ventricle, and “wraps” which merely limit the magnitude of the expansion of the left ventricle during diastolic filling without a substantial shape change.
While it is desirable to reduce wall stress for the treatment of heart failure, to slow or reverse the disease process and to increase heart wall muscle shortening and pumping efficiency, it is also desirable to maintain or improve stroke volume and allow for variable preload.
Improving muscle shortening both total length change and extent at end systole, is particularly important in symptomatic heart failure wherein the heart has decreased left ventricle function and has enlarged. Full cycle splinting can be used to obtain a substantial increase in muscle shortening. Improved shortening will lead to an increase in pump function, and chronically may result in muscle strengthening and reversal of the disease because of increased pumping efficiency. The increase in shortening should be balanced against a reduction in chamber volume.
In asymptomatic, early stage heart failure, it may be possible to use only a restrictive device or method as elevated wall stress is considered to be an initiator of muscle damage and chamber enlargement. Restrictive devices and methods acting during diastole will reduce the maximum wall stress experienced during end diastole and early systole. It should be understood that restrictive devices and methods can be used in combination with full cycle splinting to more precisely control or manipulate stress reduction throughout the cardiac cycle.
The present invention is directed at reducing wall stress in a failing heart. Diastolic wall stress is considered to be an initiator of muscle damage and chamber enlargement. For this reason, it is desirable to reduce diastolic wall stress to prevent the progression of the disease. The significant impact of stress occurs at all stages and functional levels of heart failure, however, independent of the original causes. For example, in asymptomatic early stages of heart failure, mechanical stress can lead to symptomatic heart failure marked by an enlarged heart with decreased left ventricle function. As the heart enlarges, mechanical stress on the heart wall increases proportionally to the increasing radius of the heart in accordance with LaPlace's Law. It can thus be appreciated that as stress increases in symptomatic heart failure, those factors that contributed to increasing stress also increase. Thus, the progression of the disease accelerates to late stage heart failure, end stage heart failure and death unless the disease is treated.
Three parameters influence mechanical stress on the muscle. These are: (1) muscle mass, i.e., as reflected by the thickness of the muscle; (2) pressure in the chamber which is a function of the resistance to blood flow of the patient's vasculature and the volume of blood within the patient; and (3) chamber geometry. The present invention pertains to devices and methods for directly and passively changing chamber geometry to lower wall stress. In addition to treatment of heart failure, the devices and methods of the present invention also lend themselves to application in the case of a decrease in cardiac function caused by, for example, acute myocardial infarction.
The devices disclosed herein for changing chamber geometry are referred to as “splints”. In addition to splints, wraps which can be placed around the heart can limit muscle stress without the chamber shape change. When a wrap is used, wall stress is merely transferred to the wrap, while the generally globular shape of the heart is maintained. A wrap could be used in conjunction with a splint to modulate heart wall stress reduction at various stages of the cardiac cycle.
The present invention includes a number of splint embodiments. Splints and wraps can be classified by where in the cardiac cycle they engage the heart wall, i.e., mechanically limit the size of the left ventricle in the case of wraps and change the geometry of the ventricle in the case of splints. If a splint or wrap only begins to engage during diastolic filling, the splint can be termed a “restrictive splint”. If the splint or wrap is engaged throughout the cardiac cycle, both during diastolic filling and systolic contraction and ejection, the splint can be termed a “full cycle splint”. The wrap will generally be a restrictive device which begins to engage during diastolic filling to increase the elastance (reduces compliance) of the chamber. If a wrap is made from elastic material it may engage full cycle, but the force required to elongate the wrap will increase as diastolic filling progresses, preload strain will be reduced without an improvement in systolic contraction.
In
If heart A, as shown in
Each of the splints, wraps and other devices disclosed in this application preferably do not substantially deform during the cardiac cycle such that the magnitude of the resistance to the expansion or contraction of the heart provided by these devices is reduced by substantial deflection. It is, however, contemplated that devices which deflect or elongate elastically under load are within the scope of the present invention, though not preferred. The materials from which each device are formed must be biocompatible and are preferably configured to be substantially atraumatic.
The distinction between restrictive devices, such as restrictive splints and wraps, and full cycle splints and wraps, can be better understood by reference to
An arbitrary beginning of the normal cardiac cycle N can be chosen at end diastole 14, where the left ventricle is full, the aortic valve is closed. Just after end diastole 14, systole begins, the sarcomere muscles become active and the mitral valve closes, increasing muscle stress without substantially shortening (sometimes referred to as “isovolumic contraction”). Stress increases until the aortic valve opens at 16. Isotonic shortening begins and stress decreases and the muscles shorten until end systole 18, where the blood has been ejected from the left ventricle and the aortic valve closes. After end systole 18, diastole begins, the muscles relax without elongating until diastolic filling begins when the mitral valve opens at 20. The muscles then elongate while the mitral valve remains open during diastolic filling until end diastole 14. The total muscle shortening and lengthening during the normal cycle N is NS.
An analogous cycle F also occurs in a failing heart. As the left ventricle has dilated, in accordance with LaPlace's Law, the larger radius of a dilated left ventricle causes stress to increase at a given blood pressure. Consequently, a failing heart must compensate to maintain the blood pressure. The compensation for the increased stress is reflected in the shift to the right of failing heart cardiac cycle F relative to the normal cycle N. The stress at end diastole 22 is elevated over the stress at end diastole 14 of the normal heart. A similar increase can be seen for the point at which the aortic valve opens 24, end systole 26 and the beginning of diastolic filling 28 relative to the analogous points for the normal cycle N. Muscle shortening and elongation FS throughout the cycle is also reduced in view of the relative steepening of the diastolic curve 12 to the right and the flatter contractility curve Fc relative to the normal contractility Nc.
By reference to the heart cycle stress strain graph of
The effect on the stress/strain relationship of a full cycle splint will acutely shift the entire stress/strain curve F for the cycle to the left. That is, stress is reduced at both end diastole 22 and end systole 26. Muscle shortening and elongation Fs will increase acutely. If, as in the case of a restrictive splint, muscle contractility FC improves, the entire cardiac cycle curve F will shift further to the left reducing mechanical stress still further.
The type and magnitude of shape change are important factors in determining the effectiveness of splinting. There are several types of lower stress cardiac geometries that can be created from an enlarged globular left ventricular chamber typically associate with heart failure. They include lobed, disc-like, narrowed elongate, and multiple vertically stacked bulbs.
For a restrictive splint, the horizontal cross sections 30 and 40 will have a generally circular shape, i.e., a non-splinted shape at end systole. As diastolic filling proceeds, the radius of the circular shape will continue to increase until the splint engages. At the point the splint engages, the lobed shape will begin to form. In the case of the two lobe splinting of
In the case of a full cycle splint, at end systole, the splint will already be engaged. Thus, for a full cycle splint at end systole, the horizontal cross section of the chamber will not have the normal generally circular shape. Rather, at end systole, the horizontal cross sections 30 and 40 will have a lobed shape such as shown in
In view of LaPlace's Law which states that stress is directly proportional to radius of curvature, it can be appreciated that whether the radius is increasing or decreasing during diastolic filling, will have an impact on heart pumping performance. Where R is increasing during diastolic filling, wall stress will increase more rapidly than where R is decreasing. The number of lobes that are created can significantly influence the level of end diastolic muscle stress reduction achieved through splinting. Eventually adding additional lobes forms a configuration which approaches a behavior similar to a wrap. If a wrap is substantially inelastic, or of sufficient size, a wrap will only engage the heart wall at some stage of diastolic filling. If the wrap is substantially inelastic, as pressure increases in the chamber during diastolic filling, stress in the heart wall muscle will increase until the wrap fully engages and substantially all additional muscle elongating load created by increased chamber pressure will be shifted to the wrap. No further elongation of the chamber muscles disposed in a horizontal cross section through the wrap and the chamber will occur. Thus, inelastic wraps will halt additional preload muscle strain (end diastolic muscle stretch).
The type of shape change illustrated in
The magnitude of shape change in the case of full cycle splinting becomes very important as full cycle splinting generally reduces chamber volume more than restrictive splinting. Although as with restrictive devices, the type of shape change is also important to allow for variable preload strain. Both restrictive device and full cycle splints reduce chamber volume as they reduce the cross sectional area of the chamber during the cardiac cycle. The magnitude of the shape change can vary from very slight at end diastole, such that chamber volume is only slightly reduced from the unsplinted end diastolic volume, to an extreme reduction in volume, for example, complete bifurcation by transventricular splint. The magnitude of the shape change, for example, as measured by the ratio of splint length to non-splinted ventricular diameter, is preferably modulated to reduce muscle stress while not overly reducing chamber volume. For full cycle splint, the reduction of chamber volume is compensated for by increased contractile shortening, which in turn leads to an increased ejection fraction, i.e., the ratio of the stroke volume to chamber volume. For given stress/volume and stress/shortening relationships, there will be a theoretical optimum maximal stroke volume. Clinically, 20% to 30% stress reduction is expected to be attainable through full cycle bi-lobe splinting. See U.S. Pat. No. 5,961,440 and the discussion further herein for calculation of stress reduction for idealized bi-lobe splinting.
When using the full cycle and restrictive devices described herein, caution should be exercised to limit the pressure on the coronary vasculature. In the case of transventricular splints, valve structure, electrical pathways and coronary vasculature should be avoided.
Splints 52 can be restrictive or full cycle splints. Band Splints 51 are shown as restrictive band splints as in
Pads 72 are shown engaged with heart A to change the shape of ventricle B in
Frame 70 is preferably rigid enough that pads 72 could be disposed on the heart for full cycle splinting and sufficiently adjustable that pads 72 could be spaced further apart for restrictive splinting. Pad 73 accomplishes restrictive splinting. Frame 71, pads 72 and 73 of splint 70 are made of a biocompatible material. Pads 72 and 73 are preferably substantially atraumatic.
If band splint 100 substantially elongated elastically under normal operating loads, it could be friction fit to heart A and act full cycle, limiting muscle stress at end diastole as well end systole. Band splint 100 could be sutured into place or otherwise held on heart A and act as a restrictive device. If band 101 were securely fastened to heart A, bands 102 could limit the vertical elongation of heart A during diastolic filling.
Band splint 110 could be made of the same materials as band splint 100. Band splint 110 can also be used in a manner similar to band splint 100 except that band splint 110 would limit the vertical elongation of the ventricles less than band splint 100.
The length of band 143 can be seen in its entirety in
When line 161 is placed in heart A, one end of line 161 can be tied to bar 162 at 164. Line 161 can then encircle the heart and be drawn through eyelet 162 adjacent the beginning of line 161 at 164. Line 161 can then be drawn through one eyelet 163 of a lower pair of eyelets to encircle the heart again. This process continues until line 161 is tied to an eyelet 163 at 165. It can be appreciated that wrap 160 could be used as a restrictive or full cycle device depending on the diameter of loop formed by line 161.
If elongate bar 224 is sized such that device 220 does not engage at end diastole, but rather anchor pad 228 first engages during systolic contraction, device 220 can fall into a third class of device neither full cycle nor restrictive. Such a device would reduce wall stress during a portion of systolic contraction including end systole, but not reduce wall stress during end diastole, thus maintaining maximum preload.
Band 222 of device 220 is preferably formed from a web material or other fabric. Band 220 is preferably does not elongate substantially during diastolic filling. Members 224, 226 and 228 are formed from materials which remain substantially rigid under the influences of the forces encountered during the cardiac cycle.
Line 261 is preferably made from atraumatic biocompatible material. The diameter of line 261 is preferably sufficiently great that cutting of heart A does not occur during diastolic filling.
Device 270 can be formed from material similar to that used to form device 260. Additionally, device 270 can be made to function as a restrictive device or full cycle device in a manner similar to that of device 260.
Line 261 and line 267 could be disposed within a tube to avoid cheese cutting of the myocardium. The tube may be highly flexible, yet durable enough to prevent the line from cheese cutting through the myocardium of the heart. Devices 260 and 270 could extend through the septum or right ventricle to avoid forming lobes in right ventricle C.
It should be understood that although devices disclosed herein are described in relation to the left ventricle of a human heart, these devices could also be used to reduce the radius or cross-sectional area of the other chambers of a human heart in transverse or vertical directions, or at an angle between the transverse and vertical.
Each of the various embodiments of the present invention can be made from materials which can remain implanted in the human body indefinitely. Such biocompatible materials are well-known to those skilled in the art of clinical medical devices.
In use, the various embodiments of the present invention are placed in or adjacent the human heart to reduce the radius or cross-section area of at least one chamber of the heart. This is done to reduce wall stress or tension in the heart or chamber wall to slow, stop or reverse failure of the heart.
To discuss further the stress reduction associated with splinting,
h=R2 COS(θ/2)
l=2R2 SIN(θ/2)
R2=R1π/(2π−θ)
From these relationships, the area of the figure eight cross-section can be calculated by:
A2=2π(R2)2(1−θ/2π)+hl
Where chamber 48′ is unsplinted as shown in
Thus, for example, with an original cylindrical radius of four centimeters and a pressure within the chamber of 140 mm of mercury, the wall tension T in the walls of the-cylinder is 104.4 newtons. When a 3.84 cm splint is placed as shown in
Numerous characteristics and advantages of the invention covered by this document have been set forth in the foregoing description. It will be understood, however, that this disclosure is, in many respects, only illustrative. Changes may be made in details, particularly in matters of shape, size and ordering of steps without exceeding the scope of the invention. The invention's scope is defined in the language of the claims.
This application is a continuation of U.S. application Ser. No. 10/127,731 (“the '731 application”) of Cyril J. SCHWEICH Jr. et al. for HEART WALL TENSION REDUCTION APPARATUS AND METHOD, filed on Apr. 23, 2002 now U.S. Pat. No. 7,883,539, which is a continuation-in-part of U.S. application Ser. No. 09/985,361 of Cyril J. SCHWEICH, Jr. et al. for HEART WALL TENSION REDUCTION APPARATUS AND METHOD, filed Nov. 2, 2001, now U.S. Pat. No. 6,589,160, which is a continuation of U.S. application Ser. No. 09/697,597, filed Oct. 27, 2000, now U.S. Pat. No. 6,332,864, which is a continuation of Application No. 09/492,777, filed Jan. 28, 2000, now U.S. Pat. No. 6,162,168, which is a continuation of Application No. 08/778,277, filed Jan. 2, 1997, now U.S. Pat. No. 6,050,936. The '731 application also is a continuation-in-part of U.S. application Ser. No. 09/843,078 of Todd J. MORTIER et al. for STRESS REDUCTION APPARATUS AND METHOD, filed Apr. 27, 2001, now U.S. Pat. No. 6,402,680, which is a continuation of Application No. 09/522,068, filed Mar. 9, 2000, now U.S. Pat. No. 6,264,602, which is a continuation of Application No. 09/124,321, filed Jul. 29, 1998, now U.S. Pat. No. 6,077,214. The entirety of each of the above applications is incorporated herein by reference.
Number | Name | Date | Kind |
---|---|---|---|
963899 | Kistler | Jul 1910 | A |
3019790 | Militana | Feb 1962 | A |
3656185 | Carpentier | Apr 1972 | A |
3980068 | Karsten et al. | Sep 1976 | A |
4035849 | Angell et al. | Jul 1977 | A |
4055861 | Carpentier et al. | Nov 1977 | A |
4192293 | Asrican | Mar 1980 | A |
4217665 | Bex et al. | Aug 1980 | A |
4261342 | Aranguren Duo | Apr 1981 | A |
4281659 | Farrar et al. | Aug 1981 | A |
4300564 | Furihata | Nov 1981 | A |
4306319 | Kaster | Dec 1981 | A |
4343048 | Ross et al. | Aug 1982 | A |
4372293 | Vijil-Rosales | Feb 1983 | A |
4409974 | Freedland | Oct 1983 | A |
4536893 | Parravicini | Aug 1985 | A |
4548203 | Tacker, Jr. et al. | Oct 1985 | A |
4554929 | Samson et al. | Nov 1985 | A |
4579120 | MacGregor | Apr 1986 | A |
4592342 | Salmasian | Jun 1986 | A |
4629459 | Ionescu et al. | Dec 1986 | A |
4632101 | Freedland | Dec 1986 | A |
4690134 | Snyders | Sep 1987 | A |
4705040 | Mueller et al. | Nov 1987 | A |
4936857 | Kulik | Jun 1990 | A |
4944753 | Burgess et al. | Jul 1990 | A |
4960424 | Grooters | Oct 1990 | A |
4991578 | Cohen | Feb 1991 | A |
4997431 | Isner et al. | Mar 1991 | A |
5061277 | Carpentier et al. | Oct 1991 | A |
5104407 | Lam et al. | Apr 1992 | A |
5106386 | Isner et al. | Apr 1992 | A |
5131905 | Grooters | Jul 1992 | A |
RE34021 | Mueller et al. | Aug 1992 | E |
5152765 | Ross et al. | Oct 1992 | A |
5156621 | Navia et al. | Oct 1992 | A |
5169381 | Snyders | Dec 1992 | A |
5192314 | Daskalakis | Mar 1993 | A |
5250049 | Michael | Oct 1993 | A |
5256132 | Snyders | Oct 1993 | A |
5258015 | Li et al. | Nov 1993 | A |
5284488 | Sideris | Feb 1994 | A |
5300087 | Knoepfler | Apr 1994 | A |
5312642 | Chesterfield et al. | May 1994 | A |
5350399 | Erlebacher et al. | Sep 1994 | A |
5360444 | Kusuhara | Nov 1994 | A |
5376112 | Duran | Dec 1994 | A |
5383840 | Heilman et al. | Jan 1995 | A |
5385528 | Wilk | Jan 1995 | A |
5389096 | Aita et al. | Feb 1995 | A |
5397331 | Himpens et al. | Mar 1995 | A |
5417709 | Slater | May 1995 | A |
5433727 | Sideris | Jul 1995 | A |
5445600 | Abdulla | Aug 1995 | A |
5450860 | O'Connor | Sep 1995 | A |
5452733 | Sterman et al. | Sep 1995 | A |
5458574 | Machold et al. | Oct 1995 | A |
5496305 | Kittrell et al. | Mar 1996 | A |
5509428 | Dunlop | Apr 1996 | A |
5522884 | Wright | Jun 1996 | A |
5533958 | Wilk | Jul 1996 | A |
5571215 | Sterman et al. | Nov 1996 | A |
5584803 | Stevens et al. | Dec 1996 | A |
5593424 | Northrup, III | Jan 1997 | A |
5607471 | Seguin et al. | Mar 1997 | A |
5655548 | Nelson et al. | Aug 1997 | A |
5665092 | Mangiardi et al. | Sep 1997 | A |
5674279 | Wright et al. | Oct 1997 | A |
5682906 | Sterman et al. | Nov 1997 | A |
5683364 | Zadini et al. | Nov 1997 | A |
5702343 | Alferness | Dec 1997 | A |
5713954 | Rosenberg et al. | Feb 1998 | A |
5718725 | Sterman et al. | Feb 1998 | A |
5738649 | Macoviak | Apr 1998 | A |
5755783 | Stobie et al. | May 1998 | A |
5758663 | Wilk et al. | Jun 1998 | A |
5766234 | Chen et al. | Jun 1998 | A |
5776189 | Khalid | Jul 1998 | A |
5800334 | Wilk | Sep 1998 | A |
5800528 | Lederman et al. | Sep 1998 | A |
5800531 | Cosgrove et al. | Sep 1998 | A |
5807384 | Mueller | Sep 1998 | A |
5814097 | Sterman et al. | Sep 1998 | A |
5824066 | Gross | Oct 1998 | A |
5824069 | Lemole | Oct 1998 | A |
5840059 | March et al. | Nov 1998 | A |
5849005 | Garrison et al. | Dec 1998 | A |
5855601 | Bessler et al. | Jan 1999 | A |
5855614 | Stevens et al. | Jan 1999 | A |
5865791 | Whayne et al. | Feb 1999 | A |
5876436 | Vanney et al. | Mar 1999 | A |
5888240 | Carpentier et al. | Mar 1999 | A |
5902229 | Tsitlik et al. | May 1999 | A |
5928281 | Huynh et al. | Jul 1999 | A |
5944738 | Amplatz et al. | Aug 1999 | A |
5957977 | Melvin | Sep 1999 | A |
5961440 | Schweich, Jr. et al. | Oct 1999 | A |
5961539 | Northrup, III et al. | Oct 1999 | A |
5961549 | Nguyen et al. | Oct 1999 | A |
5967990 | Thierman et al. | Oct 1999 | A |
5971910 | Tsitlik et al. | Oct 1999 | A |
5971911 | Wilk | Oct 1999 | A |
5972022 | Huxel | Oct 1999 | A |
5984857 | Buck et al. | Nov 1999 | A |
5984917 | Fleischman et al. | Nov 1999 | A |
5999678 | Murphy-Chutorian et al. | Dec 1999 | A |
6001126 | Nguyen-Thien-Nhon | Dec 1999 | A |
6019722 | Spence et al. | Feb 2000 | A |
6024096 | Buckberg | Feb 2000 | A |
6024756 | Huebsch et al. | Feb 2000 | A |
6045497 | Schweich, Jr. et al. | Apr 2000 | A |
6050936 | Schweich, Jr. et al. | Apr 2000 | A |
6059715 | Schweich, Jr. et al. | May 2000 | A |
6071303 | Laufer | Jun 2000 | A |
6077214 | Mortier et al. | Jun 2000 | A |
6077218 | Alferness | Jun 2000 | A |
6079414 | Roth | Jun 2000 | A |
6085754 | Alferness et al. | Jul 2000 | A |
6086532 | Panescu et al. | Jul 2000 | A |
6095968 | Snyders | Aug 2000 | A |
6102944 | Huynh et al. | Aug 2000 | A |
6110100 | Talpade | Aug 2000 | A |
6113536 | Aboul-Hosn et al. | Sep 2000 | A |
6113636 | Ogle | Sep 2000 | A |
6117159 | Huebsch et al. | Sep 2000 | A |
6120520 | Saadat et al. | Sep 2000 | A |
6123662 | Alferness et al. | Sep 2000 | A |
6125852 | Stevens et al. | Oct 2000 | A |
6126590 | Alferness | Oct 2000 | A |
6129758 | Love | Oct 2000 | A |
6132438 | Fleischman et al. | Oct 2000 | A |
6143025 | Stobie et al. | Nov 2000 | A |
6155968 | Wilk | Dec 2000 | A |
6155972 | Nauertz et al. | Dec 2000 | A |
6162168 | Schweich, Jr. et al. | Dec 2000 | A |
6165119 | Schweich, Jr. et al. | Dec 2000 | A |
6165120 | Schweich, Jr. et al. | Dec 2000 | A |
6165121 | Alferness | Dec 2000 | A |
6165122 | Alferness | Dec 2000 | A |
6165183 | Kuehn et al. | Dec 2000 | A |
6169922 | Alferness et al. | Jan 2001 | B1 |
6174279 | Girard | Jan 2001 | B1 |
6174332 | Loch et al. | Jan 2001 | B1 |
6179791 | Krueger | Jan 2001 | B1 |
6182664 | Cosgrove | Feb 2001 | B1 |
6183411 | Mortier et al. | Feb 2001 | B1 |
6183512 | Howanec, Jr. et al. | Feb 2001 | B1 |
6190408 | Melvin | Feb 2001 | B1 |
6193648 | Krueger | Feb 2001 | B1 |
6197053 | Cosgrove et al. | Mar 2001 | B1 |
6206004 | Schmidt et al. | Mar 2001 | B1 |
6206820 | Kazi et al. | Mar 2001 | B1 |
6210432 | Solem et al. | Apr 2001 | B1 |
6217610 | Carpentier et al. | Apr 2001 | B1 |
6221013 | Panescu et al. | Apr 2001 | B1 |
6221103 | Melvin | Apr 2001 | B1 |
6221104 | Buckberg et al. | Apr 2001 | B1 |
6224540 | Lederman et al. | May 2001 | B1 |
6230714 | Alferness et al. | May 2001 | B1 |
6231518 | Grabek et al. | May 2001 | B1 |
6231561 | Frazier et al. | May 2001 | B1 |
6231602 | Carpentier et al. | May 2001 | B1 |
6238334 | Easterbrook, III et al. | May 2001 | B1 |
6241654 | Alferness | Jun 2001 | B1 |
6245102 | Jayaraman | Jun 2001 | B1 |
6245105 | Nguyen et al. | Jun 2001 | B1 |
6250308 | Cox | Jun 2001 | B1 |
6251061 | Hastings et al. | Jun 2001 | B1 |
6258021 | Wilk | Jul 2001 | B1 |
6258023 | Rogers et al. | Jul 2001 | B1 |
6260552 | Mortier et al. | Jul 2001 | B1 |
6260820 | Chowdhury | Jul 2001 | B1 |
6261222 | Schweich, Jr. | Jul 2001 | B1 |
6264602 | Mortier et al. | Jul 2001 | B1 |
6266550 | Selmon et al. | Jul 2001 | B1 |
6269819 | Oz et al. | Aug 2001 | B1 |
6283993 | Cosgrove et al. | Sep 2001 | B1 |
6290674 | Roue et al. | Sep 2001 | B1 |
6293906 | Vanden Hoek et al. | Sep 2001 | B1 |
6309370 | Haim et al. | Oct 2001 | B1 |
6312447 | Grimes | Nov 2001 | B1 |
6314322 | Rosenberg | Nov 2001 | B1 |
6328727 | Frazier et al. | Dec 2001 | B1 |
6331157 | Hancock | Dec 2001 | B2 |
6332863 | Schweich, Jr. et al. | Dec 2001 | B1 |
6332864 | Schweich, Jr. et al. | Dec 2001 | B1 |
6332893 | Mortier et al. | Dec 2001 | B1 |
6338712 | Spence et al. | Jan 2002 | B2 |
6343605 | Lafontaine | Feb 2002 | B1 |
6360749 | Jayaraman | Mar 2002 | B1 |
6361545 | Macoviak et al. | Mar 2002 | B1 |
6370429 | Alferness et al. | Apr 2002 | B1 |
6375608 | Alferness | Apr 2002 | B1 |
6379366 | Fleischman et al. | Apr 2002 | B1 |
6402679 | Mortier et al. | Jun 2002 | B1 |
6402680 | Mortier et al. | Jun 2002 | B2 |
6402781 | Langberg et al. | Jun 2002 | B1 |
6406420 | McCarthy et al. | Jun 2002 | B1 |
6406422 | Landesberg | Jun 2002 | B1 |
6409759 | Peredo | Jun 2002 | B1 |
6409760 | Melvin | Jun 2002 | B1 |
6416459 | Haindl | Jul 2002 | B1 |
6419669 | Frazier et al. | Jul 2002 | B1 |
6423051 | Kaplan et al. | Jul 2002 | B1 |
6425856 | Shapland et al. | Jul 2002 | B1 |
6432039 | Wardle | Aug 2002 | B1 |
6432059 | Hickey | Aug 2002 | B2 |
6436088 | Frazier et al. | Aug 2002 | B2 |
6439237 | Buckberg et al. | Aug 2002 | B1 |
6443949 | Altman | Sep 2002 | B2 |
6450171 | Buckberg et al. | Sep 2002 | B1 |
6458100 | Roue et al. | Oct 2002 | B2 |
6461366 | Seguin | Oct 2002 | B1 |
6478729 | Rogers et al. | Nov 2002 | B1 |
6482146 | Alferness et al. | Nov 2002 | B1 |
6488706 | Solymar | Dec 2002 | B1 |
6494825 | Talpade | Dec 2002 | B1 |
6508756 | Kung et al. | Jan 2003 | B1 |
6511426 | Hossack et al. | Jan 2003 | B1 |
6514194 | Schweich, Jr. et al. | Feb 2003 | B2 |
6520904 | Melvin | Feb 2003 | B1 |
6537198 | Vidlund et al. | Mar 2003 | B1 |
6537203 | Alferness et al. | Mar 2003 | B1 |
6537314 | Langberg et al. | Mar 2003 | B2 |
6544167 | Buckberg et al. | Apr 2003 | B2 |
6544180 | Doten et al. | Apr 2003 | B1 |
6547821 | Taylor et al. | Apr 2003 | B1 |
6569198 | Wilson et al. | May 2003 | B1 |
6572529 | Wilk | Jun 2003 | B2 |
6582355 | Alferness et al. | Jun 2003 | B2 |
6587734 | Okuzumi | Jul 2003 | B2 |
6589160 | Schweich, Jr. et al. | Jul 2003 | B2 |
6592619 | Melvin | Jul 2003 | B2 |
6595912 | Lau et al. | Jul 2003 | B2 |
6602182 | Milbocker | Aug 2003 | B1 |
6602184 | Lau et al. | Aug 2003 | B2 |
6612278 | Kampichlet | Sep 2003 | B2 |
6612978 | Lau et al. | Sep 2003 | B2 |
6612979 | Lau et al. | Sep 2003 | B2 |
6616596 | Milbocker | Sep 2003 | B1 |
6616684 | Vidlund et al. | Sep 2003 | B1 |
6619291 | Hlavka | Sep 2003 | B2 |
6622730 | Ekvall et al. | Sep 2003 | B2 |
6626821 | Kung et al. | Sep 2003 | B1 |
6626930 | Allen et al. | Sep 2003 | B1 |
6629534 | St. Goar et al. | Oct 2003 | B1 |
6629921 | Schweich, Jr. et al. | Oct 2003 | B1 |
6645139 | Haindl | Nov 2003 | B2 |
6651671 | Donlon et al. | Nov 2003 | B1 |
6656221 | Taylor et al. | Dec 2003 | B2 |
6663558 | Lau et al. | Dec 2003 | B2 |
6669708 | Nissenbaum et al. | Dec 2003 | B1 |
6673009 | Vanden Hoek et al. | Jan 2004 | B1 |
6676702 | Mathis | Jan 2004 | B2 |
6681773 | Murphy et al. | Jan 2004 | B2 |
6682474 | Lau et al. | Jan 2004 | B2 |
6682475 | Cox et al. | Jan 2004 | B2 |
6682476 | Alferness et al. | Jan 2004 | B2 |
6685620 | Gifford, III et al. | Feb 2004 | B2 |
6685627 | Jayaraman | Feb 2004 | B2 |
6685646 | Cespedes et al. | Feb 2004 | B2 |
6689048 | Vanden Hoek et al. | Feb 2004 | B2 |
6692458 | Forman et al. | Feb 2004 | B2 |
6695768 | Levine et al. | Feb 2004 | B1 |
6695866 | Kuehn et al. | Feb 2004 | B1 |
6701929 | Hussein | Mar 2004 | B2 |
6702732 | Lau et al. | Mar 2004 | B1 |
6702763 | Murphy et al. | Mar 2004 | B2 |
6702826 | Liddicoat et al. | Mar 2004 | B2 |
6706065 | Langberg et al. | Mar 2004 | B2 |
6709456 | Langberg et al. | Mar 2004 | B2 |
6712804 | Roue et al. | Mar 2004 | B2 |
6716158 | Raman et al. | Apr 2004 | B2 |
6719767 | Kimblad | Apr 2004 | B1 |
6723038 | Schroeder et al. | Apr 2004 | B1 |
6726716 | Marquez | Apr 2004 | B2 |
6726717 | Alfieri et al. | Apr 2004 | B2 |
6730016 | Cox et al. | May 2004 | B1 |
6733525 | Yang et al. | May 2004 | B2 |
6740107 | Loeb et al. | May 2004 | B2 |
6752813 | Goldfarb et al. | Jun 2004 | B2 |
6755777 | Schweich, Jr. et al. | Jun 2004 | B2 |
6755779 | Vanden Hoek et al. | Jun 2004 | B2 |
6767362 | Schreck | Jul 2004 | B2 |
6769434 | Liddicoat et al. | Aug 2004 | B2 |
6776754 | Wilk | Aug 2004 | B1 |
6790231 | Liddicoat et al. | Sep 2004 | B2 |
6793673 | Kowalsky et al. | Sep 2004 | B2 |
6797001 | Mathis et al. | Sep 2004 | B2 |
6800090 | Alferness et al. | Oct 2004 | B2 |
6805710 | Bolling et al. | Oct 2004 | B2 |
6810882 | Langberg et al. | Nov 2004 | B2 |
6814700 | Mueller et al. | Nov 2004 | B1 |
6824562 | Mathis et al. | Nov 2004 | B2 |
6837247 | Buckberg et al. | Jan 2005 | B2 |
6846296 | Milbocker et al. | Jan 2005 | B1 |
6875224 | Grimes | Apr 2005 | B2 |
6876887 | Okuzumi | Apr 2005 | B2 |
6881185 | Vanden Hoek et al. | Apr 2005 | B2 |
6887192 | Whayne et al. | May 2005 | B1 |
6890353 | Cohn et al. | May 2005 | B2 |
6893392 | Alferness | May 2005 | B2 |
6896652 | Alferness et al. | May 2005 | B2 |
6902522 | Walsh et al. | Jun 2005 | B1 |
6908426 | Shapland et al. | Jun 2005 | B2 |
6908478 | Alferness et al. | Jun 2005 | B2 |
6913608 | Liddicoat et al. | Jul 2005 | B2 |
6918917 | Nguyen et al. | Jul 2005 | B1 |
6921407 | Nguyen et al. | Jul 2005 | B2 |
6949122 | Adams et al. | Sep 2005 | B2 |
6951534 | Girard et al. | Oct 2005 | B2 |
6955689 | Ryan et al. | Oct 2005 | B2 |
6959711 | Murphy et al. | Nov 2005 | B2 |
6960229 | Mathis et al. | Nov 2005 | B2 |
6962605 | Cosgrove et al. | Nov 2005 | B2 |
6966926 | Mathis | Nov 2005 | B2 |
6976995 | Mathis et al. | Dec 2005 | B2 |
6986775 | Morales et al. | Jan 2006 | B2 |
6989028 | Lashinski et al. | Jan 2006 | B2 |
6994093 | Murphy et al. | Feb 2006 | B2 |
6997865 | Alferness et al. | Feb 2006 | B2 |
6997951 | Solem et al. | Feb 2006 | B2 |
7004958 | Adams et al. | Feb 2006 | B2 |
7011682 | Lashinski et al. | Mar 2006 | B2 |
7022064 | Alferness et al. | Apr 2006 | B2 |
7025719 | Alferness et al. | Apr 2006 | B2 |
7037334 | Hlavka et al. | May 2006 | B1 |
7044967 | Solem et al. | May 2006 | B1 |
7052487 | Cohn et al. | May 2006 | B2 |
7056280 | Buckberg et al. | Jun 2006 | B2 |
7060021 | Wilk | Jun 2006 | B1 |
7063722 | Marquez | Jun 2006 | B2 |
7070618 | Streeter | Jul 2006 | B2 |
7090695 | Solem et al. | Aug 2006 | B2 |
7112207 | Allen et al. | Sep 2006 | B2 |
7115110 | Frazier et al. | Oct 2006 | B2 |
7125420 | Rourke et al. | Oct 2006 | B2 |
7153258 | Alferness et al. | Dec 2006 | B2 |
7163507 | Alferness | Jan 2007 | B2 |
7166071 | Alferness | Jan 2007 | B2 |
7166126 | Spence et al. | Jan 2007 | B2 |
7179282 | Alferness et al. | Feb 2007 | B2 |
7186264 | Liddicoat et al. | Mar 2007 | B2 |
7189199 | McCarthy et al. | Mar 2007 | B2 |
7192442 | Solem et al. | Mar 2007 | B2 |
7214181 | Shapland et al. | May 2007 | B2 |
7220277 | Arru et al. | May 2007 | B2 |
7226467 | Lucatero et al. | Jun 2007 | B2 |
7229469 | Witzel et al. | Jun 2007 | B1 |
7241310 | Taylor et al. | Jul 2007 | B2 |
7252632 | Shapland et al. | Aug 2007 | B2 |
7255674 | Alferness | Aug 2007 | B2 |
7261684 | Alferness | Aug 2007 | B2 |
7264587 | Chin | Sep 2007 | B2 |
7270676 | Alferness et al. | Sep 2007 | B2 |
7275546 | Buckberg et al. | Oct 2007 | B2 |
7278964 | Alferness | Oct 2007 | B2 |
7291168 | Macoviak et al. | Nov 2007 | B2 |
7296577 | Lashinski et al. | Nov 2007 | B2 |
7309354 | Mathis et al. | Dec 2007 | B2 |
7311728 | Solem et al. | Dec 2007 | B2 |
7311729 | Mathis et al. | Dec 2007 | B2 |
7311731 | Lesniak et al. | Dec 2007 | B2 |
7326174 | Cox et al. | Feb 2008 | B2 |
7329280 | Bolling et al. | Feb 2008 | B2 |
7351200 | Alferness | Apr 2008 | B2 |
7361137 | Taylor et al. | Apr 2008 | B2 |
7364588 | Mathis et al. | Apr 2008 | B2 |
7373207 | Lattouf | May 2008 | B2 |
7377940 | Ryan et al. | May 2008 | B2 |
7381182 | Raman et al. | Jun 2008 | B2 |
7381220 | Macoviak et al. | Jun 2008 | B2 |
7390293 | Jayaraman | Jun 2008 | B2 |
7410461 | Lau et al. | Aug 2008 | B2 |
7419466 | Vanden Hoek et al. | Sep 2008 | B2 |
20010003986 | Cosgrove | Jun 2001 | A1 |
20010005787 | Oz et al. | Jun 2001 | A1 |
20010009976 | Panescu et al. | Jul 2001 | A1 |
20010014800 | Frazier et al. | Aug 2001 | A1 |
20010014811 | Hussein | Aug 2001 | A1 |
20010018611 | Solem et al. | Aug 2001 | A1 |
20010021874 | Carpentier et al. | Sep 2001 | A1 |
20010029314 | Alferness et al. | Oct 2001 | A1 |
20010034551 | Cox | Oct 2001 | A1 |
20010037123 | Hancock | Nov 2001 | A1 |
20010039434 | Frazier et al. | Nov 2001 | A1 |
20010039435 | Roue et al. | Nov 2001 | A1 |
20010039436 | Frazier et al. | Nov 2001 | A1 |
20010041821 | Wilk | Nov 2001 | A1 |
20010041914 | Frazier et al. | Nov 2001 | A1 |
20010041915 | Roue et al. | Nov 2001 | A1 |
20010044568 | Langberg et al. | Nov 2001 | A1 |
20010047122 | Vanden Hoek et al. | Nov 2001 | A1 |
20010049492 | Frazier et al. | Dec 2001 | A1 |
20020007216 | Melvin | Jan 2002 | A1 |
20020013571 | Goldfarb et al. | Jan 2002 | A1 |
20020016628 | Langberg et al. | Feb 2002 | A1 |
20020019580 | Lau et al. | Feb 2002 | A1 |
20020022880 | Melvin | Feb 2002 | A1 |
20020026092 | Buckberg et al. | Feb 2002 | A1 |
20020026094 | Roth | Feb 2002 | A1 |
20020028981 | Lau et al. | Mar 2002 | A1 |
20020029783 | Stevens et al. | Mar 2002 | A1 |
20020032364 | Lau et al. | Mar 2002 | A1 |
20020042554 | Alferness et al. | Apr 2002 | A1 |
20020045798 | Lau et al. | Apr 2002 | A1 |
20020045799 | Lau et al. | Apr 2002 | A1 |
20020045800 | Lau et al. | Apr 2002 | A1 |
20020052538 | Lau et al. | May 2002 | A1 |
20020056461 | Jayaraman | May 2002 | A1 |
20020058855 | Schweich, Jr. et al. | May 2002 | A1 |
20020065449 | Wardle | May 2002 | A1 |
20020065465 | Panescu et al. | May 2002 | A1 |
20020065554 | Streeter | May 2002 | A1 |
20020068850 | Vanden Hoek et al. | Jun 2002 | A1 |
20020077532 | Gannoe et al. | Jun 2002 | A1 |
20020082647 | Alferness et al. | Jun 2002 | A1 |
20020087173 | Alferness et al. | Jul 2002 | A1 |
20020091296 | Alferness | Jul 2002 | A1 |
20020103511 | Alferness et al. | Aug 2002 | A1 |
20020103532 | Langberg et al. | Aug 2002 | A1 |
20020103533 | Langberg et al. | Aug 2002 | A1 |
20020111533 | Melvin | Aug 2002 | A1 |
20020111567 | Vanden Hoek et al. | Aug 2002 | A1 |
20020111636 | Fleischman et al. | Aug 2002 | A1 |
20020133055 | Haindl | Sep 2002 | A1 |
20020143250 | Panescu et al. | Oct 2002 | A1 |
20020151766 | Shapland et al. | Oct 2002 | A1 |
20020151961 | Lashinski et al. | Oct 2002 | A1 |
20020161275 | Schweich, Jr. et al. | Oct 2002 | A1 |
20020169358 | Mortier et al. | Nov 2002 | A1 |
20020169359 | McCarthy et al. | Nov 2002 | A1 |
20020169360 | Taylor et al. | Nov 2002 | A1 |
20020169502 | Mathis | Nov 2002 | A1 |
20020169504 | Alferness et al. | Nov 2002 | A1 |
20020173694 | Mortier et al. | Nov 2002 | A1 |
20020183835 | Taylor et al. | Dec 2002 | A1 |
20020183836 | Liddicoat et al. | Dec 2002 | A1 |
20020183837 | Streeter et al. | Dec 2002 | A1 |
20020183838 | Liddicoat et al. | Dec 2002 | A1 |
20020183841 | Cohn et al. | Dec 2002 | A1 |
20020188170 | Santamore et al. | Dec 2002 | A1 |
20020188350 | Arru et al. | Dec 2002 | A1 |
20030004396 | Vanden Hock et al. | Jan 2003 | A1 |
20030009081 | Rogers et al. | Jan 2003 | A1 |
20030023132 | Melvin et al. | Jan 2003 | A1 |
20030028077 | Alferness et al. | Feb 2003 | A1 |
20030032979 | Mortier et al. | Feb 2003 | A1 |
20030045771 | Schweich, Jr. et al. | Mar 2003 | A1 |
20030045776 | Alferness et al. | Mar 2003 | A1 |
20030045896 | Murphy et al. | Mar 2003 | A1 |
20030050529 | Vidlund et al. | Mar 2003 | A1 |
20030050659 | Murphy et al. | Mar 2003 | A1 |
20030060674 | Gifford, III et al. | Mar 2003 | A1 |
20030065248 | Lau et al. | Apr 2003 | A1 |
20030069467 | Lau et al. | Apr 2003 | A1 |
20030078465 | Pai et al. | Apr 2003 | A1 |
20030078653 | Vesely et al. | Apr 2003 | A1 |
20030078671 | Lesniak et al. | Apr 2003 | A1 |
20030093104 | Bonner et al. | May 2003 | A1 |
20030105519 | Fasol et al. | Jun 2003 | A1 |
20030120340 | Liska et al. | Jun 2003 | A1 |
20030130730 | Cohn et al. | Jul 2003 | A1 |
20030130731 | Vidlund et al. | Jul 2003 | A1 |
20030135267 | Solem et al. | Jul 2003 | A1 |
20030144697 | Mathis et al. | Jul 2003 | A1 |
20030149333 | Alferness | Aug 2003 | A1 |
20030153946 | Kimblad | Aug 2003 | A1 |
20030158570 | Ferrazzi | Aug 2003 | A1 |
20030166992 | Schweich, Jr. et al. | Sep 2003 | A1 |
20030171641 | Schweich, Jr. et al. | Sep 2003 | A1 |
20030171776 | Adams et al. | Sep 2003 | A1 |
20030171806 | Mathis et al. | Sep 2003 | A1 |
20030181928 | Vidlund et al. | Sep 2003 | A1 |
20030191538 | Buckberg et al. | Oct 2003 | A1 |
20030199733 | Shapland et al. | Oct 2003 | A1 |
20030212453 | Mathis et al. | Nov 2003 | A1 |
20030225454 | Mathis et al. | Dec 2003 | A1 |
20030233022 | Vidlund et al. | Dec 2003 | A1 |
20030236569 | Mathis et al. | Dec 2003 | A1 |
20040002719 | Oz et al. | Jan 2004 | A1 |
20040003819 | St. Goar et al. | Jan 2004 | A1 |
20040010305 | Alferness et al. | Jan 2004 | A1 |
20040019377 | Taylor et al. | Jan 2004 | A1 |
20040019378 | Hlavka et al. | Jan 2004 | A1 |
20040024286 | Melvin | Feb 2004 | A1 |
20040030382 | St. Goar et al. | Feb 2004 | A1 |
20040039442 | St. Goar et al. | Feb 2004 | A1 |
20040039443 | Solem et al. | Feb 2004 | A1 |
20040049115 | Murphy et al. | Mar 2004 | A1 |
20040049116 | Murphy et al. | Mar 2004 | A1 |
20040059181 | Alferness | Mar 2004 | A1 |
20040059182 | Alferness | Mar 2004 | A1 |
20040059187 | Alferness | Mar 2004 | A1 |
20040059188 | Alferness | Mar 2004 | A1 |
20040059189 | Alferness | Mar 2004 | A1 |
20040064014 | Melvin et al. | Apr 2004 | A1 |
20040073302 | Rourke et al. | Apr 2004 | A1 |
20040092962 | Thornton et al. | May 2004 | A1 |
20040093023 | Allen et al. | May 2004 | A1 |
20040102678 | Haindl | May 2004 | A1 |
20040102679 | Alferness et al. | May 2004 | A1 |
20040102839 | Cohn et al. | May 2004 | A1 |
20040102840 | Solem et al. | May 2004 | A1 |
20040111101 | Chin | Jun 2004 | A1 |
20040127983 | Mortier et al. | Jul 2004 | A1 |
20040133063 | McCarthy et al. | Jul 2004 | A1 |
20040133069 | Shapland et al. | Jul 2004 | A1 |
20040152947 | Schroeder et al. | Aug 2004 | A1 |
20040158123 | Jayaraman | Aug 2004 | A1 |
20040162610 | Liska et al. | Aug 2004 | A1 |
20040167374 | Schweich et al. | Aug 2004 | A1 |
20040167539 | Kuehn et al. | Aug 2004 | A1 |
20040171907 | Alferness et al. | Sep 2004 | A1 |
20040171908 | Alferness et al. | Sep 2004 | A1 |
20040171909 | Alferness | Sep 2004 | A1 |
20040176678 | Murphy et al. | Sep 2004 | A1 |
20040176679 | Murphy et al. | Sep 2004 | A1 |
20040176840 | Langberg et al. | Sep 2004 | A1 |
20040181121 | Alferness et al. | Sep 2004 | A1 |
20040181122 | Alferness et al. | Sep 2004 | A1 |
20040181123 | Alferness et al. | Sep 2004 | A1 |
20040181124 | Alferness | Sep 2004 | A1 |
20040181125 | Alferness et al. | Sep 2004 | A1 |
20040181126 | Buckberg et al. | Sep 2004 | A1 |
20040186342 | Vanden Hock et al. | Sep 2004 | A1 |
20040193260 | Alferness et al. | Sep 2004 | A1 |
20040199183 | Oz et al. | Oct 2004 | A1 |
20040210304 | Seguin et al. | Oct 2004 | A1 |
20040225300 | Goldfarb et al. | Nov 2004 | A1 |
20040243229 | Vidlund et al. | Dec 2004 | A1 |
20040249452 | Adams et al. | Dec 2004 | A1 |
20040267083 | McCarthy et al. | Dec 2004 | A1 |
20050004428 | Cox et al. | Jan 2005 | A1 |
20050004666 | Alfieri et al. | Jan 2005 | A1 |
20050021056 | St. Goar et al. | Jan 2005 | A1 |
20050021057 | St. Goar et al. | Jan 2005 | A1 |
20050021135 | Ryan et al. | Jan 2005 | A1 |
20050027351 | Reuter et al. | Feb 2005 | A1 |
20050027353 | Alferness et al. | Feb 2005 | A1 |
20050027369 | Eldridge et al. | Feb 2005 | A1 |
20050033419 | Alferness et al. | Feb 2005 | A1 |
20050033446 | Deem et al. | Feb 2005 | A1 |
20050038507 | Alferness et al. | Feb 2005 | A1 |
20050043792 | Solem et al. | Feb 2005 | A1 |
20050049679 | Taylor et al. | Mar 2005 | A1 |
20050049698 | Bolling et al. | Mar 2005 | A1 |
20050060030 | Lashinski et al. | Mar 2005 | A1 |
20050065598 | Mathis et al. | Mar 2005 | A1 |
20050065601 | Lee et al. | Mar 2005 | A1 |
20050071000 | Liddicoat et al. | Mar 2005 | A1 |
20050075723 | Schroeder et al. | Apr 2005 | A1 |
20050075727 | Wheatley | Apr 2005 | A1 |
20050080402 | Santamore et al. | Apr 2005 | A1 |
20050080483 | Solem et al. | Apr 2005 | A1 |
20050085688 | Girard et al. | Apr 2005 | A1 |
20050095268 | Walsh et al. | May 2005 | A1 |
20050096740 | Langberg et al. | May 2005 | A1 |
20050107810 | Morales et al. | May 2005 | A1 |
20050113635 | Whayne et al. | May 2005 | A1 |
20050113811 | Houser et al. | May 2005 | A1 |
20050119519 | Girard et al. | Jun 2005 | A9 |
20050131533 | Alfieri et al. | Jun 2005 | A1 |
20050149179 | Mathis et al. | Jul 2005 | A1 |
20050149180 | Mathis et al. | Jul 2005 | A1 |
20050149182 | Alferness et al. | Jul 2005 | A1 |
20050187619 | Mathis et al. | Aug 2005 | A1 |
20050197528 | Vanden Hoek et al. | Sep 2005 | A1 |
20050197692 | Pai et al. | Sep 2005 | A1 |
20050197693 | Pai et al. | Sep 2005 | A1 |
20050209690 | Mathis et al. | Sep 2005 | A1 |
20050216077 | Mathis et al. | Sep 2005 | A1 |
20050228217 | Alferness et al. | Oct 2005 | A1 |
20050261704 | Mathis | Nov 2005 | A1 |
20050267574 | Cohn et al. | Dec 2005 | A1 |
20050272969 | Alferness et al. | Dec 2005 | A1 |
20060004443 | Liddicoat et al. | Jan 2006 | A1 |
20060009842 | Huynh et al. | Jan 2006 | A1 |
20060020336 | Liddicoat et al. | Jan 2006 | A1 |
20060025856 | Ryan et al. | Feb 2006 | A1 |
20060030866 | Schreck | Feb 2006 | A1 |
20060030882 | Adams et al. | Feb 2006 | A1 |
20060041306 | Vidlund et al. | Feb 2006 | A1 |
20060052868 | Mortier et al. | Mar 2006 | A1 |
20060064115 | Allen et al. | Mar 2006 | A1 |
20060064116 | Allen et al. | Mar 2006 | A1 |
20060064118 | Kimblad | Mar 2006 | A1 |
20060069430 | Rahdert et al. | Mar 2006 | A9 |
20060106456 | Machold et al. | May 2006 | A9 |
20060111607 | Alferness et al. | May 2006 | A1 |
20060116756 | Solem et al. | Jun 2006 | A1 |
20060116757 | Lashinski et al. | Jun 2006 | A1 |
20060137697 | Murphy et al. | Jun 2006 | A1 |
20060142854 | Alferness et al. | Jun 2006 | A1 |
20060149122 | Shapland et al. | Jul 2006 | A1 |
20060149123 | Vidlund et al. | Jul 2006 | A1 |
20060149368 | Spence | Jul 2006 | A1 |
20060155165 | Vanden Hoek et al. | Jul 2006 | A1 |
20060161040 | McCarthy et al. | Jul 2006 | A1 |
20060173536 | Mathis et al. | Aug 2006 | A1 |
20060184203 | Martin et al. | Aug 2006 | A1 |
20060184241 | Marquez | Aug 2006 | A1 |
20060195012 | Mortier et al. | Aug 2006 | A1 |
20060212114 | Menicanti et al. | Sep 2006 | A1 |
20060229717 | Cohn et al. | Oct 2006 | A1 |
20060235265 | Alferness et al. | Oct 2006 | A1 |
20060241340 | Schroeder et al. | Oct 2006 | A1 |
20060247492 | Streeter | Nov 2006 | A1 |
20060252984 | Rahdert et al. | Nov 2006 | A1 |
20060258900 | Buckberg et al. | Nov 2006 | A1 |
20070004962 | Alferness et al. | Jan 2007 | A1 |
20070038293 | St.Goar et al. | Feb 2007 | A1 |
20070050020 | Spence | Mar 2007 | A1 |
20070055303 | Vidlund et al. | Mar 2007 | A1 |
20070066879 | Mathis et al. | Mar 2007 | A1 |
20070100442 | Solem et al. | May 2007 | A1 |
20070112244 | McCarthy et al. | May 2007 | A1 |
20070118155 | Goldfarb et al. | May 2007 | A1 |
20070129598 | Raman et al. | Jun 2007 | A1 |
20070129737 | Goldfarb et al. | Jun 2007 | A1 |
20070156235 | Rourke et al. | Jul 2007 | A1 |
20070161846 | Nikolic et al. | Jul 2007 | A1 |
20070208211 | Shapland et al. | Sep 2007 | A1 |
20070213814 | Liddicoat et al. | Sep 2007 | A1 |
20070225547 | Alferness | Sep 2007 | A1 |
20070288090 | Solem et al. | Dec 2007 | A1 |
20080033235 | Shapland et al. | Feb 2008 | A1 |
20080051807 | St. Goar et al. | Feb 2008 | A1 |
20080091191 | Witzel et al. | Apr 2008 | A1 |
20080097489 | Goldfarb et al. | Apr 2008 | A1 |
20080097593 | Bolling et al. | Apr 2008 | A1 |
20080097594 | Mathis et al. | Apr 2008 | A1 |
20080125622 | Walsh et al. | May 2008 | A1 |
20080140191 | Mathis et al. | Jun 2008 | A1 |
20080147184 | Lattouf | Jun 2008 | A1 |
20080154359 | Salgo et al. | Jun 2008 | A1 |
20080161638 | Taylor et al. | Jul 2008 | A1 |
20080167714 | St. Goar et al. | Jul 2008 | A1 |
20080183194 | Goldfarb et al. | Jul 2008 | A1 |
20080183284 | Ryan et al. | Jul 2008 | A1 |
20080188861 | Ryan et al. | Aug 2008 | A1 |
20080195200 | Vidlund et al. | Aug 2008 | A1 |
20080208331 | McCarthy et al. | Aug 2008 | A1 |
20080215008 | Nance et al. | Sep 2008 | A1 |
Number | Date | Country |
---|---|---|
32 27 984 | Feb 1984 | DE |
36 14 292 | Nov 1987 | DE |
42 34 127 | May 1994 | DE |
295 00 381 | Jul 1995 | DE |
296 19 294 | Aug 1997 | DE |
298 24 017 | Jun 1998 | DE |
198 26 675 | Mar 1999 | DE |
199 47 885 | Apr 2000 | DE |
0 583 012 | Feb 1994 | EP |
0 792 621 | Sep 1997 | EP |
0 820 729 | Jan 1998 | EP |
1 129 736 | Sep 2001 | EP |
2 768 324 | Mar 1999 | FR |
2214428 | Sep 1989 | GB |
9 200 878 | Dec 1993 | NL |
9119465 | Dec 1991 | WO |
9506447 | Mar 1995 | WO |
9516476 | Jun 1995 | WO |
WO 9516407 | Jun 1995 | WO |
9604852 | Feb 1996 | WO |
WO 9602197 | Feb 1996 | WO |
9640356 | Dec 1996 | WO |
WO 9714286 | Apr 1997 | WO |
9724082 | Jul 1997 | WO |
9724083 | Jul 1997 | WO |
9724101 | Jul 1997 | WO |
WO 9741779 | Nov 1997 | WO |
9803213 | Jan 1998 | WO |
9814136 | Apr 1998 | WO |
WO 9817347 | Apr 1998 | WO |
9818393 | May 1998 | WO |
9826738 | Jun 1998 | WO |
9829041 | Jul 1998 | WO |
9832382 | Jul 1998 | WO |
WO 9858598 | Dec 1998 | WO |
9900059 | Jan 1999 | WO |
9911201 | Mar 1999 | WO |
9913777 | Mar 1999 | WO |
WO 9913936 | Mar 1999 | WO |
WO 9916350 | Apr 1999 | WO |
WO 9922784 | May 1999 | WO |
9930647 | Jun 1999 | WO |
9944534 | Sep 1999 | WO |
9944680 | Sep 1999 | WO |
WO 9944969 | Sep 1999 | WO |
9952470 | Oct 1999 | WO |
WO 9953977 | Oct 1999 | WO |
9956655 | Nov 1999 | WO |
WO 9966969 | Dec 1999 | WO |
0002500 | Jan 2000 | WO |
WO 0003759 | Jan 2000 | WO |
WO 0006026 | Feb 2000 | WO |
WO 0006028 | Feb 2000 | WO |
0013722 | Mar 2000 | WO |
0018320 | Apr 2000 | WO |
0027304 | May 2000 | WO |
0028912 | May 2000 | WO |
0028918 | May 2000 | WO |
WO 0025842 | May 2000 | WO |
WO 0025853 | May 2000 | WO |
0036995 | Jun 2000 | WO |
0042919 | Jul 2000 | WO |
WO 0042950 | Jul 2000 | WO |
WO 0042951 | Jul 2000 | WO |
0045735 | Aug 2000 | WO |
0062727 | Oct 2000 | WO |
WO 0060995 | Oct 2000 | WO |
WO 0061033 | Oct 2000 | WO |
WO 0062715 | Oct 2000 | WO |
0103608 | Jan 2001 | WO |
WO 0100111 | Jan 2001 | WO |
0121070 | Mar 2001 | WO |
0121098 | Mar 2001 | WO |
0121099 | Mar 2001 | WO |
WO 0119291 | Mar 2001 | WO |
WO 0119292 | Mar 2001 | WO |
WO 0121247 | Mar 2001 | WO |
WO 0126557 | Apr 2001 | WO |
WO 0128432 | Apr 2001 | WO |
WO 0149217 | Jul 2001 | WO |
WO 0150981 | Jul 2001 | WO |
WO 0154562 | Aug 2001 | WO |
WO 0154618 | Aug 2001 | WO |
WO 0154745 | Aug 2001 | WO |
WO 0167985 | Sep 2001 | WO |
WO 0170116 | Sep 2001 | WO |
WO 0178625 | Oct 2001 | WO |
WO 0185061 | Nov 2001 | WO |
WO 0191667 | Dec 2001 | WO |
WO 0195830 | Dec 2001 | WO |
WO 0195831 | Dec 2001 | WO |
WO 0195832 | Dec 2001 | WO |
WO 0211625 | Feb 2002 | WO |
WO 0213726 | Feb 2002 | WO |
WO 0219917 | Mar 2002 | WO |
WO 0228450 | Apr 2002 | WO |
WO 0230292 | Apr 2002 | WO |
WO 0230335 | Apr 2002 | WO |
WO 0234167 | May 2002 | WO |
WO 0238081 | May 2002 | WO |
WO 0243617 | Jun 2002 | WO |
WO 02053206 | Jul 2002 | WO |
WO 02060352 | Aug 2002 | WO |
WO 02062263 | Aug 2002 | WO |
WO 02062270 | Aug 2002 | WO |
WO 02062408 | Aug 2002 | WO |
WO 02064035 | Aug 2002 | WO |
WO 02076284 | Oct 2002 | WO |
WO 02078576 | Oct 2002 | WO |
WO 02085251 | Oct 2002 | WO |
WO 02096275 | Dec 2002 | WO |
WO 03001893 | Jan 2003 | WO |
WO 03007778 | Jan 2003 | WO |
WO 03015611 | Feb 2003 | WO |
WO 03022131 | Mar 2003 | WO |
WO 03059209 | Jul 2003 | WO |
Number | Date | Country | |
---|---|---|---|
20100274076 A1 | Oct 2010 | US |
Number | Date | Country | |
---|---|---|---|
Parent | 10127731 | Apr 2002 | US |
Child | 12832507 | US | |
Parent | 09697597 | Oct 2000 | US |
Child | 09985361 | US | |
Parent | 09492777 | Jan 2000 | US |
Child | 09697597 | US | |
Parent | 08778277 | Jan 1997 | US |
Child | 09492777 | US | |
Parent | 09522068 | Mar 2000 | US |
Child | 09843078 | US | |
Parent | 09124321 | Jul 1998 | US |
Child | 09522068 | US |
Number | Date | Country | |
---|---|---|---|
Parent | 09985361 | Nov 2001 | US |
Child | 10127731 | US | |
Parent | 09843078 | Apr 2001 | US |
Child | 10127731 | Apr 2002 | US |